Cartesian Therapeutics Inc
RNAC
Get informed when a big investor buys or sells
+ FollowMarket Cap$221.54M
Close$
$3.63
42% downside
Current Fair Value
42% downsideOvervalued by 42% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $221.54 Million |
|---|---|
| Enterprise Value | $114.75 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.02 |
| Beta | 0.56 |
| Outstanding Shares | 26,855,158 |
Return
| Return on Equity | 102.47% |
|---|---|
| Return on Assets | -52.63% |
| Return on Invested Capital | -25.78% |
Valuation & Multiples
| P/E Ratio | -1.33 |
|---|---|
| PEG | -1.1 |
| Price to Sales | - |
| Price to Book Ratio | -1.04 |
| Enterprise Value to Revenue | 64.65 |
| Enterprise Value to EBIT | -1.63 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.84
Average shareholder expectationRevenue Estimate
$219,800
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.87
Average shareholder expectationRevenue Estimate
$188,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 84.85% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 27.53%▲ 7.68% |
|---|---|
| Total Invested | $43.93M▲ 18.04% |
| Investors Holding | 82▲ 12.00% |
ESG Score
No data
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...